| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
Psyence Biomedical Ltd.$3.06
-0.12 (-3.95%)
D 22Pipeline Score Fair Value Pharma · Clinical
Market Cap
4.19 M
EPS
-
P/E Ratio
-
Value Trade
1.68 M
-18.65 %
Week
-49.13 %
1 Month
55.3 %
3 Month
-57.68 %
6 Month
-99.99 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
13.54 K
52 Week Range
1.92 - 74.94
% held by Insiders
-
% held by Institutions
58.55 %
Enterprise Value
-
Total Shares
1.02 M
Short %
13.42 %
Float Shares
968.00 K
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Psyence Biomedical Ltd.
152Total events
0Upcoming
37Tier-1 (high impact)
2023 – 2026Coverage
Event history 152
Apr 23, 2026
▲First Patient DosedNPX-5Trial
First patient dosed in Phase IIb trial of NPX-5 for Adjustment Disorder
Adjustment Disorder in patients with cancer in a palliative care settingsource ↗
Apr 8, 2026
▲Enrollment UpdateNPX-5Trial
Expansion of clinical site network from three to five sites in Australia
Adjustment Disorder in patients with cancer in a palliative care settingsource ↗
Mar 3, 2026
▲Manufacturing MilestoneNPX-5CMC / Inspection
Export of GMP-manufactured NPX-5 capsules to Australia
Feb 25, 2026
Feb 2, 2026
Jan 22, 2026
◆Quarterly UpdateCorporate
Annual and Special Meeting of Shareholders to consider financial statements, auditor appointment, director election, and share consolidation
Jan 20, 2026
◆Reverse Stock SplitCorporate
Postponement of previously announced 1-for-6.25 reverse stock split effective date
Jan 12, 2026
Jan 5, 2026
▲Manufacturing MilestoneCMC / Inspection
First Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride
Jan 5, 2026
▲Trial InitiationpsilocybinTrial
Phase 2b psilocybin clinical trial underway
mental health disorderssource ↗
2026
◆Topline ReadoutNPX-5Clinical Data
Top-line results expected in 2026
Adjustment Disorder in patients with cancersource ↗
Drug Pipeline Intelligence
D22
Pipeline Score $5M
Pipeline ValueFair Value
Valuation Signal1
Drugs Scored1.2x
rNPV / MCap Top 20%
Micro Cap (rank 726 of 906)
Percentile RankPsyence Biomedical Ltd. faces pipeline headwinds (22/100), with $387M risk-adjusted pipeline value, led by Psilocybin therapy in Adjustment Disorder (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Psilocybin therapy Small molecule | Adjustment Disorder | Phase 2 | NCT07072728 | 19% | $387M | RECRUITING | 87 | STALLED | B (63) | Jul 30, 2027 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PBM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PBM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PBMPsyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
Psyence BioMed Ltd. announced a strategic engagement initiative in the U.S. to promote GMP ibogaine research and manufacturing. The company's leadership will meet with key stakeholders to discuss regulatory considerations and scientific infrastructure. This initiative follows recent U.S. policy changes supporting psychedelic research, and Psyence aims to educate on compliant ibogaine production.
Read more →PBMPsyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Psyence Biomedical Ltd. has commenced patient dosing in its Phase IIb clinical trial assessing NPX-5, a psilocybin treatment for Adjustment Disorder in cancer patients receiving palliative care. This trial marks the first significant human evaluation of NPX-5 and aims to evaluate its safety and efficacy across multiple sites in Australia. The company seeks to generate critical clinical data to inform future development and regulatory pathways while addressing a significant psychological need in this patient population.
Read more →PBMPsyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Psyence Biomedical Ltd. has established itself as the only licensed supplier of pharmaceutical-grade ibogaine by developing a vertically integrated platform for sourcing, manufacturing, and supplying ibogaine. The company has positioned itself to support the scientific and clinical research community as regulatory interest in ibogaine grows. By securing direct access to the natural source of ibogaine in Africa and maintaining a GMP-compliant inventory, Psyence aims to address the existing supply gaps in the market. Their capabilities will enable continued research and potential commercialization of ibogaine-based therapies.
Read more →PBMPsyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
Psyence BioMed has welcomed reports of an upcoming U.S. executive order aimed at evaluating the safety and therapeutic potential of ibogaine, a compound thought to aid in treating PTSD and addiction. The move is seen as a necessary step toward regulated research in areas with limited treatment options. The company emphasizes the importance of controlled clinical research and has also established a GMP-compliant manufacturing presence for ibogaine. With increased interest in ibogaine, Psyence aims to support scientific progress through ethical sourcing and a robust supply chain.
Read more →PBMPsyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Psyence Biomedical Ltd. announced the expansion of its Australian clinical site network from three to five sites, including the addition of Ramsay Health Care and NeuroCentrix. This expansion is aimed at strengthening recruitment and accelerating enrollment for its ongoing Phase IIb clinical trial evaluating natural psilocybin for treating Adjustment Disorder in cancer patients. The company's move is expected to broaden its operational efficiency and support patient dosing. CEO Jody Aufrichtig emphasized the importance of this growth for generating meaningful clinical data.
Read more →PBMPsyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
Psyence BioMed has successfully exported its GMP-manufactured psilocybin product NPX-5 to Australia for a Phase IIb clinical trial. This trial aims to evaluate the efficacy of natural psilocybin in treating Adjustment Disorder in cancer patients. The company emphasizes its commitment to quality and regulatory compliance while pioneering the use of nature-derived psychedelics in mental health care.
Read more →PBMPsyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
Psyence Biomedical Ltd. (Nasdaq: PBM) announced that PsyLabs exercised its put option, enabling a strategic equity investment where Psyence will acquire shares in PsyLabs. This exercise aims to strengthen the collaboration between the two companies, enhancing Psyence's access to high-quality psychedelic manufacturing resources. The transaction involves a Share-for-Share Exchange, resulting in PsyLabs obtaining roughly 49.98% ownership of Psyence's common shares. While this aligns with Psyence's long-term growth objectives, it poses risks of dilution for existing shareholders and significant influence over governance.
Read more →PBMPsyence BioMed Announces Results of Annual and Special Meeting of Shareholders
Psyence Biomedical Ltd. announced the results of its Annual and Special Meeting of Shareholders held on February 12, 2026. Shareholders approved all proposed business matters, including the election of directors and the appointment of auditors. Additionally, they authorized the board to consolidate shares at a ratio of up to 250:1, pending regulatory approvals.
Read more →PBMPsyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
Psyence Biomedical Ltd. has ratified a put option agreement with PsyLabs, allowing for a potential equity investment in the company. This agreement is part of a strategic relationship that enhances Psyence's access to PsyLabs' advanced manufacturing capabilities for pharmaceutical-grade psychedelics. The partnership aims to streamline Psyence's commercialization efforts and assures a reliable supply of these compounds for clinical and commercial programs. However, the success of this agreement hinges on PsyLabs' continued operational and regulatory compliance.
Read more →PBMPsyence BioMed Approves a Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway The Put Option Agreement positions Psyence BioMed for potential significant future equity pa
Psyence BioMed has ratified a Put Option Agreement with PsyLabs, which allows PsyLabs to require Psyence to make an equity investment in exchange for access to its manufacturing capabilities. This agreement is designed to secure a reliable supply of pharmaceutical-grade psychedelics as Psyence advances its commercialization strategy. The partnership positions Psyence to mitigate risks related to regulatory and supply-chain challenges, enabling more secure planning for future clinical programs. The arrangement also preserves the company's financial flexibility while aiming to strengthen their product pipeline.
Read more →PBMPsyence BioMed Announces Settlement of Shareholder Litigation
Psyence Biomedical Ltd. has announced a settlement agreement to resolve a direct shareholder claim made by KAOS Capital Ltd. The settlement includes a payment of $1.5 million to KAOS and a retraction of the allegations made against the company. While the company denies any wrongdoing, it opted for the settlement to avoid further litigation and associated costs.
Read more →PBMPsyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Psyence Biomedical Ltd. has announced the effective date for its 1-for-6.25 reverse stock split, which will take effect on February 2, 2026. This decision follows earlier Board approvals for share consolidations and aims to enhance the company's trading performance. The total number of issued shares will decrease significantly, and there may be some impact on shareholders who hold shares through brokers. The company continues to focus on psychedelic-based therapeutics and its Nasdaq listing under the symbol 'PBM'.
Read more →PBMPsyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
Psyence Biomedical Ltd. has announced the adjournment of its annual and special shareholder meeting, originally set for January 22, 2026, due to not achieving the necessary quorum. The meeting has been rescheduled for February 12, 2026, in Cape Town, South Africa. The company is currently working with proxy agents to secure a sufficient number of shareholders for the reconvened meeting. The record date for determining shareholders eligible to attend remains unchanged.
Read more →PBMPsyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
Psyence Biomedical Ltd. has announced the postponement of its previously planned reverse stock split, which was set to take effect on January 20, 2026. The decision follows internal considerations by the Board of Directors, who will determine a new effective date in the future. Until then, the company's shares will continue to trade on a split-unadjusted basis under the ticker PBM.
Read more →PBMPsyence Biomedical Ltd. 121 Richmond Steet West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN  that an annual and special meeting (the &#
Psyence Biomedical Ltd. has announced an annual and special meeting for shareholders scheduled for January 22, 2026, in Cape Town. The meeting will address various agenda items, including the review of financial statements, appointment of auditors, election of directors, and a potential consolidation of common shares. Shareholders are encouraged to participate and submit proxies in advance to ensure their votes are counted.
Read more →PBMPsyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
Psyence BioMed has approved a 2026 Financial Strategy aimed at enhancing shareholder value, which includes a share buyback program. The decision follows a strategic review of the company's financial position and market conditions. The board believes the current share price does not reflect the company's true value and that repurchasing shares could benefit remaining shareholders. However, the execution of this program is contingent upon future market conditions and liquidity considerations.
Read more →PBMto this report. This discussion contains forward -looking statements that involve risks, uncertainties, and assumptions. Actual results may differ materially from those anticipated in these forward -looking statements as
Psyence Biomedical Ltd. is set to hold its annual and special meeting of shareholders on January 22, 2026, in Cape Town, South Africa. Key items on the agenda include the review of financial statements, appointment of auditors, the election of directors, and proposed share consolidation. Shareholders are encouraged to participate and may vote in person or by proxy. The management has prepared a circular detailing the proposals to be discussed
Read more →PBMPsyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash
Psyence Biomedical Ltd. has successfully produced GMP-compliant ibogaine hydrochloride, marking a significant milestone as the first Nasdaq-listed company to do so. With a strong cash position of $12 million and no debt, the company is well-prepared to advance its psychedelic therapeutics. Additionally, a change in the Board of Directors was announced, with Graham Patrick appointed to fill the vacancy left by Christopher Bull.
Read more →PBMPsyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
Psyence Biomedical Ltd. has received approval from the Bellberry Human Research Ethics Committee for the use of its PsyLabs psilocybin product in a Phase IIb clinical trial. This trial will evaluate psilocybin-assisted psychotherapy for Adjustment Disorder in cancer patients. The company is well-positioned with strong cash reserves and plans to activate additional clinical sites to enhance patient recruitment.
Read more →PBMPsyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
Psyence BioMed's CEO Jody Aufrichtig highlighted the company's significant achievements in 2025, describing it as a turning point for clinical progress and financial stability. The company successfully dosed its first patients in a Phase IIb trial for psilocybin-assisted psychotherapy and secured its supply chain for ibogaine through investment in PsyLabs. With a strong cash position of over USD $9 million and commitments to expand into longevity science, Psyence BioMed is poised for growth in the coming year. Additionally, regulatory developments in Australia may facilitate wider access to psilocybin-assisted therapies.
Read more →PBMPsyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program
Psyence Biomedical Ltd. has announced a groundbreaking research initiative focused on the potential impacts of psilocybin on longevity. This positions the company as the first publicly listed entity to investigate psilocybin's effects on aging markers in collaboration with esteemed researchers in South Africa. The study aims to evaluate various biological mechanisms associated with aging, such as oxidative stress and inflammation, under the guidance of a recognized neuroscientist. The initiative is part of a broader trend gaining attention as aging populations seek innovative health solutions.
Read more →PBMPsyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets
Psyence Biomedical Ltd. has secured a sustainable supply of high-potency iboga bark through its partnership with PsyLabs, marking a significant milestone in its clinical development of ibogaine for substance use disorders. The ibogaine produced is GMP-compliant, ensuring it meets clinical standards. This achievement enhances Psyence's position in the ibogaine sector and underscores its commitment to ethical sourcing and community engagement.
Read more →PBMPsyence Biomedical Ltd. Unaudited Condensed Consolidated Interim Financial Statements For the three and six months ended
Psyence Biomedical Ltd. reported its unaudited condensed consolidated interim financial statements for the three and six months ending September 30, 2025. The company's total assets increased substantially to $12.81 million, reflecting growth in cash reserves and investments. However, Psyence is encountering significant financial challenges, reporting a net loss of approximately $1.99 million for the period. The company continues its commitment to research and development of psilocybin-based therapies and is conducting clinical trials for treating mental health disorders.
Read more →PBMPsyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs
Psyence BioMed has established ibogaine operations in Africa through its investment in PsyLabs, becoming the only publicly listed psychedelics company with manufacturing capabilities on the continent. This strategic move enhances the company's supply chain and positions it to meet the growing demand for psychedelic therapies. The investment aligns with increasing global interest in ibogaine as a treatment for addiction and mental health disorders, supported by recent research and funding initiatives.
Read more →PBMPsyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care
Psyence Biomedical Ltd. has successfully dosed multiple patients in its Phase IIb clinical trial evaluating psilocybin for Adjustment Disorder in palliative care. The trial, which is the only active Australian program using natural psilocybin for this condition, has expanded to three clinical sites. The study aims to provide pivotal evidence for regulatory approval and enhance the understanding of psilocybin's efficacy and safety.
Read more →PBMPsyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
Psyence Biomedical Ltd. has announced a follow-on investment of USD $3,500,000 in PsyLabs to enhance its supply of psychedelic compounds for clinical research. This investment builds on a previous USD $500,000 investment and strengthens their partnership, ensuring access to high-quality, sustainable ingredients. The move positions Psyence BioMed as a leader in the psychedelic therapeutics market.
Read more →PBMSUBSCRIPTION AGREEMENT between THE SUBSCRIBER LISTED IN THE SCHEDULE OF PARTICULARS and PSYENCE LABS LTD. WHEREBY THE PARTIES AGREE AS FOLLOWS - 1 INTERPRETATION 1.1 In this Agreement - 1.1.1 clause headings are for conv
Psyence Labs Ltd. has formalized a subscription agreement with Psyence Biomed II Corp., which involves the issuance of 1,750 shares at a total subscription price of $3,500,000. The agreement was signed by authorized representatives from both parties, marking a significant investment into Psyence Labs. This collaboration indicates ongoing confidence in the company's strategic direction and market potential.
Read more →PBMPsyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
Psyence Biomedical Ltd. (Nasdaq: PBM) announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Dr. Neil Maresky will present the company's business strategy and pipeline. A webinar for investors is scheduled for September 16, 2025, to discuss ongoing clinical programs.
Read more →PBMCorporate Update, August 2025
Psyence BioMed (PBM) has reported significant advancements in its clinical programs, including partnerships for trial execution and the establishment of a Steering Committee for Alcohol Use Disorder research. The company maintains a strong financial position with $11.4 million in cash and has regained Nasdaq compliance. Upcoming initiatives include a webinar featuring the Scientific Advisory Board to discuss the clinical vision for psychedelic therapies.
Read more →PBMPsyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production
Psyence Biomedical Ltd. has announced a successful collaboration with PsyLabs, resulting in the production of a GMP-aligned Ibogaine Total Alkaloid extract. This high-purity extract meets all safety standards for food-grade consumption, showcasing PsyLabs' commitment to pharmaceutical innovation. The partnership aims to enhance the scalability and compliance of psychedelic APIs, addressing the growing demand in the market.
Read more →PBMPsyence BioMed Chief of Global Impact to speak at Psychedelic Science 2025 Investors, Entrepreneurs, and Industry Experts to Convene at the Premier Psychedelic Science Business Forum hosted by Multidisciplinary Associati
Psyence BioMed has announced that its Chief of Global Impact, Mary-Elizabeth Gifford, will be a featured speaker at the Psychedelic Science 2025 conference, taking place from June 16-20, 2025, in Denver, Colorado. The conference is expected to gather industry leaders, investors, and policymakers to explore advancements in psychedelic research and its applications. Gifford aims to promote discussions on ethical business practices in the psychedelic space, emphasizing the importance of integrity in patient care and shareholder value. Psyence BioMed's involvement positions the company as a key player in the commercial development of nature-derived psilocybin therapies.
Read more →PBMMaster Services Agreement Date: 21 st May 2025 Parties: Southern Star Research Pty Ltd ACN 103 120 896 of 1 Merriwa Street, Gordon NSW 2072 Australia (" Southern Star Research ") Psyence Australia Pty Ltd ABN 88 665 259
Southern Star Research and Psyence Australia have entered into a Master Services Agreement effective from May 21, 2025. The agreement details the roles and responsibilities of each party, particularly concerning investigational products and liability during clinical trials. Both parties have set terms for audits and confidentiality, with conditions regarding negligence and misconduct. The agreement signifies a formal collaboration between the two entities, although specific project details are not provided.
Read more →PBMInvestor Presentation Nasdaq: PBM May 2025 2 Psyence BioMedical Ltd. / Healing Minds with Science . Changing Lives with Nature Forward Looking Statements This presentation ("Presentation") is being issued by Psyence Biom
Psyence BioMedical Ltd. has issued an investor presentation detailing forward-looking statements regarding its future operations and product developments. The presentation emphasizes caution to investors, highlighting that it does not constitute an official offer or solicitation for securities. Furthermore, it outlines significant risks, including the company's need to gain regulatory approvals for its psilocybin product candidate and the uncertainties surrounding the success of its clinical trials. The company advises investors to consider these risks before making any financial commitments.
Read more →PBMPsyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split
Psyence BioMed has announced the effective date for a 1-for-7.97 reverse stock split, following shareholder approval for a consolidation ratio of up to 1-for-50. The consolidation is set to take place on May 5, 2025, allowing the company's shares to begin trading on a post-consolidated basis. This move is primarily aimed at regaining compliance with Nasdaq's minimum bid price requirement. Approximately 583,263 shares will remain outstanding post-consolidation, with no fractional shares issued.
Read more →PBMSent via Electronic Delivery to: neil@psyencebiomed.com; taryn@psyencebiomed.com; bpoignant@donohoeadvisory.com; kmoxley@donohoeadvisory.com
Psyence Biomedical Ltd. faces possible delisting from the Nasdaq Capital Market after failing to maintain a minimum bid price of $1 per share for 30 consecutive business days. A decision from a Nasdaq Hearings Panel has temporarily extended the monitoring period for one year, but if the company fails to meet continued listing standards during this time, they will be subject to immediate delisting. The company can appeal this determination by April 23, 2025, and has to submit a hearing request to stay the delisting process.
Read more →PBMLEVEL 7, 330 COLLINS STREET, MELBOURNE VIC 3000 PSYENCE AUSTRALIA info@psyencebiomed.com +1 416-477-1708 www.psyencebiomed.com SOUTHERN STAR RESEARCH PTY LTD (ACN 103 120 896) 1 Merriwa Street, Gordon NSW 2072 Australia
Psyence Australia Pty Ltd has announced a Letter of Intent to appoint Southern Star Research as the Contract Research Organization for their Phase IIb clinical trial. The trial will evaluate the proprietary botanical drug candidate PEX010 aimed at treating Adjustment Disorder in terminal cancer patients. Both parties are currently in negotiations to finalize the Definitive Contract by May 31, 2025, which will detail the services and terms involved in the trial. The agreement underscores a collaborative effort to advance clinical research in this therapeutic area.
Read more →PBMCorporate Update: Psyence Biomedical LTD Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing Company executives will host a corporate webinar for investors and
Psyence Biomedical LTD is advancing its multi-asset strategy in psychedelic medicine, focusing on clinical trials and scalable manufacturing. The company is currently conducting a Phase IIb clinical trial for adjustment disorder in patients with cancer in Australia, capitalizing on favorable regulatory conditions. Psyence aims to enhance its market position through strategic partnerships and has established a Scientific Advisory Board to guide its research. The firm is well-equipped financially to pursue its long-term goals, with several initiatives aimed at addressing significant unmet medical needs in the psychedelics sector.
Read more →PBMPSYENCE BIOMEDICAL LTD. NOTICE OF SPECIAL MEETING OF SHAREHOLDERS AND MANAGEMENT INFORMATION CIRCULAR IN RESPECT OF THE SPECIAL MEETING OF SHAREHOLDERS OF PSYENCE BIOMEDICAL LTD. TO BE HELD ON APRIL 16, 2025 Dated as of
Psyence Biomedical Ltd. has announced a special meeting of its shareholders scheduled for April 16, 2025. The meeting aims to discuss proposed resolutions presented in the management information circular dated March 31, 2025. Shareholders of record as of March 17, 2025, will be eligible to vote on the matters at the meeting. The corporate management encourages shareholders to carefully review the information circular and seek professional advice if necessary.
Read more →PBMPsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein
Psyence Biomedical Ltd, a subsidiary of Psyence Group Inc, has appointed Dr. Dan J. Stein to its Scientific Advisory Board. Dr. Stein's expertise in psychopharmacology is expected to bolster PBM's efforts in developing psilocybin-based therapies. The company is continuing its Phase IIb clinical trial for Adjustment Disorder and is also planning to explore treatments for Alcohol Use Disorder. A corporate webinar is scheduled for April 10, 2025, to discuss these initiatives and the future of psychedelic therapeutics.
Read more →PBMPsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
Psyence Biomedical, a NASDAQ-listed associate of Psyence Group, has appointed Dr. Albert P. Garcia-Romeu as the Chair of its newly established Scientific Advisory Board. Dr. Garcia-Romeu, a prominent figure in psychedelic research, will guide the board in exploring the therapeutic applications of psilocybin, especially for treating adjustment disorders in palliative care. The company also announced a debt settlement that includes issuing shares to a creditor. While these developments indicate a positive trajectory for research in psychedelics, there are underlying risks related to recruitment and regulatory challenges.
Read more →PBMPsyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
Psyence Biomedical Ltd. has appointed Dr. Albert P. Garcia-Romeu as the chair of its newly established Scientific Advisory Board. Dr. Garcia-Romeu, a prominent researcher in psychedelics, will guide the company as it advances its Phase IIb clinical trial of psilocybin for Adjustment Disorder in Palliative Care. The company aims to develop psychedelic-based therapeutics for mental health and addiction disorders.
Read more →PBMPsyence Biomedical Ltd. (Formerly the carve-out of Psyence Biomed Corp.) Unaudited Condensed Consolidated Interim Financial Statements For the three and six months ended
Psyence Biomedical Ltd. released its unaudited condensed consolidated interim financial statements for the six months ending September 30, 2024. The company reported total current assets of $2,243,372, an increase from previous figures, but also highlighted a substantial net deficit of $1,255,106. The financial statements show a net gain of $141,473 for the three-month period, yet the company faces significant liabilities relative to its assets. Furthermore, the potential difficulty in securing financing raises concerns about the company's future operations.
Read more →PBMPsyence Biomed Announces Closing of $2.0 Million Private Placement
Psyence Biomedical Ltd. has announced the closure of a $2 million private placement involving 1,000,000 common shares and various warrants. The proceeds are intended for working capital and corporate purposes. The offering was led by H.C. Wainwright & Co. and involves securities not registered under the Securities Act, thus requiring compliance with specific exemptions. Psyence is focused on developing nature-derived psilocybin-based therapeutics aimed at addressing mental health issues.
Read more →PBMPsyence Biomed Announces $2.0 Million Private Placement
Psyence Biomedical Ltd. announced a private placement to raise $2.0 million through the sale of 1,000,000 common shares and associated warrants. The offering is set to close around December 24, 2024, subject to customary closing conditions. The proceeds will be used for working capital and corporate purposes. However, the securities are not registered under federal securities laws, posing risks for potential investors. The success of the company also hinges on its ability to navigate regulatory hurdles and market conditions.
Read more →PBMPsyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements
Psyence Biomedical Ltd. (Nasdaq: PBM) has announced its compliance with all Nasdaq continued listing requirements after a transfer to the Nasdaq Capital Market. This change comes on the heels of a successful share consolidation aimed at addressing stock price requirements. The company maintains a solid cash position of $5.6 million and has commenced patient screening for its clinical trials. However, it faces risks concerning the execution of these trials and ongoing compliance with Nasdaq's listing rules.
Read more →PBMPsyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial
Psyence Biomedical Ltd. has reported significant progress in its active Phase IIb clinical trial involving nature-derived psilocybin for treating Adjustment Disorder in palliative care. Patient screening is currently underway, and the company expects to randomize the first patients in January. Collaborating with Australian Clinical Trial Network, Psyence Biomed is implementing patient recruitment strategies while therapist training continues. Topline results from the trial are anticipated in the second half of 2025.
Read more →PBMPsyence Biomed Executes Binding Agreements with Optimi Health Corp.
Psyence Biomedical Ltd. has executed binding agreements with Optimi Health Corp., marking a significant progression from a previous Letter of Intent. Under these agreements, Optimi will serve as the exclusive supplier of GMP-certified psilocybin extract, which will support Psyence's drug development projects, particularly for use in Palliative Care. These partnerships are expected to ensure a steady supply of quality psilocybin necessary for clinical trials and potential FDA approvals.
Read more →PBMPsyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
Psyence Group has entered agreements with its NASDAQ-listed associate, Psyence Biomedical, which include a debt-for-equity swap and a share sale agreement. Psyence Biomed will issue 337,750 common shares to Psyence Group at $3.88 per share to settle outstanding obligations under the Debt Swap Agreements. Additionally, Psyence Group will dispose of its minority stake in PsyLabs in exchange for more shares. These moves aim to strengthen their financial positions, although several risks related to share registration and market volatility remain.
Read more →PBMPsyence Biomedical Issues Shareholder Update Highlighting Recent Progress
Psyence Biomedical Ltd. has announced significant progress, including a strengthened balance sheet due to a debt-for-equity swap, and ongoing advancements in its Phase IIb clinical trial for psilocybin in patients with Adjustment Disorder. The company is optimistic about regaining compliance with Nasdaq listing requirements by year-end 2024. Psyence also reports positive valuations of its stake in PsyLabs, further enhancing their financial positioning. With multiple clinical trials and strategic initiatives underway, Psyence aims to create value in the coming years.
Read more →PBMPsyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing
Psyence Biomedical Ltd. announced a favorable result from its Nasdaq Listing Qualifications Hearing, receiving an extension to meet listing requirements by December 31, 2024. The company outlined a plan to address the $1 minimum bid price and other criteria, including a recent 1-for-75 share consolidation approved by shareholders. CEO Dr. Neil Maresky highlighted the strategic importance of maintaining Nasdaq listing for attracting institutional investors. However, the company faces risks such as potential delays in consolidation and the need to sustain compliance under the Panel's conditions.
Read more →PBMPsyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
Psyence Biomedical Ltd. has announced the effective date of its previously approved 1-for-75 share consolidation after receiving shareholder approval at its recent Annual General Meeting. This consolidation is aimed at regaining compliance with Nasdaq's minimum bid price requirement. The shares will begin trading on a post-consolidated basis on November 26, 2024, under the same ticker PBM. The company's board will adjust the outstanding warrants and issue share numbers accordingly to reflect the consolidation.
Read more →PBMPsyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
Psyence Biomedical Ltd. held its annual and special meeting on November 12, 2024, where key resolutions including a share consolidation were approved by shareholders. The company is consolidating its shares at a 75-to-1 ratio to meet Nasdaq listing requirements following a recent warning about potential delisting due to low share prices. Shareholder approval was achieved for several resolutions, including the appointment of auditors and an equity incentive plan. Despite these measures, the company faces ongoing risks related to its compliance with Nasdaq regulations.
Read more →PBMPsyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs
Psyence Biomedical Ltd. has successfully closed its acquisition of an 11.13% stake in PsyLabs, enhancing its position in the psychedelic pharmaceutical sector. The acquisition is part of a strategic partnership aimed at addressing severe mental health issues like Alcohol Use Disorder through FDA-approved psychedelics. Psyence plans to utilize PsyLabs' advanced extraction technologies in its therapeutic pipeline. However, the company is exposed to risks related to regulatory approvals and financial obligations linked to stock performance.
Read more →PBMPsyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
Psyence Group Inc. has successfully closed the disposal of its 11.13% stake in PsyLabs, transferring ownership to Psyence Biomedical Ltd. In exchange, Psyence Group will receive 2,000,000 shares of common stock from Psyence Biomed. The transaction follows a debt-for-equity swap agreement aimed at strengthening corporate financial positioning. PsyLabs' capabilities in developing nature-derived psychedelics will support future clinical trials, particularly in treating Substance Use Disorders.
Read more →PBMPsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Psyence Biomedical has announced the recruitment of the Empax Center in Perth, Australia, as the second site for its ongoing Phase IIb clinical trial of nature-derived psilocybin for Adjustment Disorder in Palliative Care. The trial aims to treat patients effectively as the company gears up for patient recruitment within the quarter. Expecting the first subject to be randomized by early December 2024, Psyence anticipates topline data in the second half of 2025. This partnership enhances clinical trial execution and positions Psyence Biomed favorably for regulatory progression contingent on trial results.
Read more →PBMPsyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Psyence Biomed has announced the recruitment of Empax Center in Perth, Australia, as the second site for its Phase IIb clinical trial testing nature-derived psilocybin for Adjustment Disorder in Palliative Care. This collaboration is expected to streamline patient recruitment, with the start of treatments anticipated soon. The company aims for topline data release in the latter half of 2025, which could lead to subsequent pivotal studies if results are favorable.
Read more →PBMto the Current Report on Form 6-K filed by the Company with the U.S. Securities and Exchange Commission on
Psyence Biomedical Ltd. (Nasdaq: PBM) held its annual and special meeting on November 12, 2024, where shareholders approved five important resolutions, including the appointment of auditors and a share consolidation. Notably, the share consolidation aims to increase the trading price to meet Nasdaq requirements. However, the company is facing potential delisting due to its stock trading under $0.10 for an extended period. Shareholders expressed significant support for the proposed equity incentive plan, indicating a positive outlook for future growth.
Read more →PBMPSYENCE BIOMEDICAL LTD. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS AND MANAGEMENT INFORMATION CIRCULAR IN RESPECT OF THE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS OF PSYENCE BIOMEDICAL LTD. TO BE HELD ON NOVEM
Psyence Biomedical Ltd. has announced its annual and special meeting of shareholders, scheduled for November 12, 2024, in New York City. Shareholders will consider several resolutions, including the adoption of amendments to the equity incentive plan and the appointment of a new auditor, MNP LLP. The meeting aims to ensure active participation from shareholders and address important company governance matters.
Read more →PBMPsyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
Psyence Biomedical Ltd. (Nasdaq: PBM) announced an update on its strategic acquisition of an equity stake in PsyLabs, highlighting progress in developing nature-derived psychedelic APIs towards E.U. Good Manufacturing Practices certification. PsyLabs successfully exported a psilocybin extract to a contract drug manufacturing organization in the UK, and has entered phase two of development, focusing on scaling the purification process. The partnership aims to ensure that PsyLabs' products meet regulatory standards and are ready for clinical trials as potential treatments for Alcohol Use Disorder and other substance use disorders. Psyence Biomed's efforts underscore its commitment to innovation in psychedelic therapeutics.
Read more →PBMPsyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
Psyence Group has entered into a debt-for-equity swap agreement with its NASDAQ-listed associate, Psyence Biomedical, involving the issuance of 2,075,920 common shares at a deemed price of US$0.50 per share. This move is intended to improve Psyence Group's liquidity and overall portfolio flexibility. The agreement carries a provision requiring Psyence Biomed to make a 'make whole payment' if share prices drop below the agreed value. Despite the potential upsides, there are risks and uncertainties regarding regulatory approval and market volatility affecting Psyence Biomed’s shares.
Read more →PBMPsyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
Psyence Biomedical Ltd. announced it will not proceed with the acquisition of Clairvoyant Therapeutics after completing due diligence. Despite this setback, the company continues to advance its Phase IIb clinical trial using nature-derived psilocybin as a treatment for Adjustment Disorder and has announced a new program targeting Substance Use Disorders, beginning with Alcohol Use Disorder. Additionally, Psyence has entered into an exclusive licensing agreement with PsyLabs to support its development efforts in this area. Further updates on its planned acquisition stake in PsyLabs are expected shortly.
Read more →PBMDEBT-FOR-EQUITY EXCHANGE AGREEMENT This DEBT-FOR-EQUITY EXCHANGE AGREEMENT (this " Agreement "), dated as of
Psyence Biomedical Ltd. has entered a Debt-for-Equity Exchange Agreement with Newcourt SPAC Sponsor, LLC, effective September 30, 2024. Under this agreement, the company will issue Common Shares to the Lender in exchange for settling a promissory note and associated debts amounting to $1,615,501. This strategic maneuver aims to strengthen Psyence's financial position by converting liabilities into equity, marking a significant business development.
Read more →PBMPsyence Group Enters into Agreement to Dispose of Stake in PsyLabs
Psyence Group has announced an agreement to sell its 11.13% stake in PsyLabs to its associated company, Psyence Biomedical Ltd., for $1.1 million in common stock. This transaction aims to enhance their collaboration in cultivating psychedelic active pharmaceutical ingredients. However, completion is contingent upon the fulfillment of certain conditions, including board and regulatory approvals and specific product development milestones to be achieved by October 31, 2024.
Read more →PBMPsyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
Psyence Biomedical Ltd. (Nasdaq: PBM) announced a conditional share sale agreement to acquire an 11.13% stake in PsyLabs for $1.1 million worth of common stock. This acquisition aims to boost Psyence's capabilities in producing psychedelic active pharmaceutical ingredients, particularly for clinical use in treating Alcohol Use Disorder and other related conditions. PsyLabs has developed a proprietary process to produce high-purity psilocybin, adding value to Psyence's existing licensing agreements. The completion of the acquisition is dependent on several conditions, including regulatory approvals and a successful product development milestone by PsyLabs.
Read more →PBMPsyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Psyence Biomed has issued a corporate update highlighting recent advancements, including the initiation of a Phase IIb study of psilocybin for Adjustment Disorder in Palliative Care. The company is expanding its pipeline to include Alcohol Use Disorder and Substance Use Disorders through an exclusive licensing agreement with Psylabs. Psyence Biomed is also planning to acquire Clairvoyant Therapeutics, which would enhance its portfolio in synthetic psilocybin treatments. Two critical data readouts from ongoing studies are projected for 2025, setting the stage for future development.
Read more →PBMEXECUTION VERSION 17 September 2024 SHARE PURCHASE AND SALE AGREEMENT between PSYENCE GROUP INC. and PSYENCE BIOMEDICAL LTD. and PSYENCE LABS LTD. Page 2 SHARE PURCHASE AND SALE AGREEMENT THIS AGREEMENT is made and enter
Psyence Group Inc. has entered into a Purchase and Sale Agreement with Psyence Biomedical Ltd. and Psyence Labs Ltd. This agreement, dated September 17, 2024, involves the sale of a significant stake in Psyence Labs Ltd. The agreement outlines the terms and conditions for the transaction and is meant to be binding on all parties involved. Additionally, it emphasizes the individual responsibilities of each party regarding the costs and execution of the agreement.
Read more →PBMPsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
Psyence Biomedical has announced the initiation of its first clinical trial site in Australia for a Phase IIb study on nature-derived psilocybin as a treatment for Adjustment Disorder in Palliative Care. The study, which will involve 87 patients, is supported by collaborations with Fluence and iNGENū, enabling efficient patient screening. Both companies believe in the potential of psilocybin to address unmet mental health needs. The first patient is expected to be randomized into the study next month.
Read more →PBMPsyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Psyence Biomed has made significant strides in its clinical pipeline, initiating a Phase IIb study of nature-derived psilocybin to treat Adjustment Disorder in Palliative Care. The company has also expanded its focus to Alcohol Use Disorder and other Substance Use Disorders through a licensing agreement with Psylabs. Additionally, Psyence announced the acquisition of Clairvoyant, which further strengthens its development pipeline. With two critical Phase II data readouts anticipated in 2025, the company is positioning itself for substantial growth in the psychedelic therapeutics market.
Read more →PBMPsyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
Psyence Biomedical Ltd. announced it received a delisting determination letter from Nasdaq after failing to meet market value requirements. The company faced a deficiency for not maintaining a market value of listed securities above $50 million and publicly held shares above $15 million. Psyence plans to request a hearing to contest the delisting, which would suspend any immediate action until the outcome. This situation raises significant concerns about the company's financial health and future operations.
Read more →PBMPsyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
Psyence Biomedical Ltd. has announced the successful initiation of its first clinical trial site in Australia for a Phase IIb study of nature-derived psilocybin aimed at treating Adjustment Disorder in Palliative Care patients. The company will evaluate different doses of psilocybin in conjunction with psychotherapy, supported by partnerships with iNGENū and Fluence. Patient screening is expected to commence soon, with the first participant anticipated to be enrolled in October. Positive trial results could pave the way for a pivotal Phase III program in the near future.
Read more →PBMPsyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
Psyence Biomedical Ltd. announced a conditional term sheet for acquiring Clairvoyant Therapeutics, a developer of psilocybin-based therapies. This acquisition aims to enhance Psyence's pipeline, particularly in addressing Alcohol Use Disorder through Clairvoyant's ongoing Phase IIb clinical trial. The transaction includes an upfront payment and milestone-based shares, with topline data from the trial expected in early 2025. However, the completion of this acquisition depends on several conditions, including successful due diligence and regulatory approvals.
Read more →PBMLICENCE AGREEMENT FOR ALCOHOL USE DISORDER AND SUBSTANCE USE DISORDER This Agreement ( Agreement ) is effective as of this 3 rd day of September 2024, ( Effective Date ) between PSYENCE UK GROUP LTD , a private company i
The effective agreement between PSYENCE UK GROUP LTD and PSYENCE BIOMEDICAL LTD centers on tackling alcohol use disorder and substance use disorder. This collaboration, effective as of September 3, 2024, outlines the terms and limitations of licensing between the two parties. However, the agreement includes a disclaimer on warranties, limiting liability for certain damages, which may impact future developments.
Read more →PBMPsyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)
Psyence Biomed has entered into a worldwide exclusive licensing agreement with PsyLabs to acquire nature-derived psilocybin for clinical trials aimed at treating alcohol use disorder (AUD) and other substance use disorders (SUDs). This partnership positions Psyence Biomed to advance innovative therapeutic options in a market with significant unmet needs. The company is set to lead a clinical trial specifically addressing AUD, while also pursuing another indication for Adjustment Disorder in patients with advanced cancer diagnoses. Both the development and commercialization of the psilocybin product will depend on the successful collaboration with PsyLabs and subsequent regulatory approvals.
Read more →PBMInvestor Presentation Nasdaq: PBM September 2024 Psyence Biomedical Ltd. / Healing Minds with Science . Changing Lives with Nature 2 This presentation (“Presentation”) is being issued by Psyence Biomedical
Psyence Biomedical Ltd. conducted an investor presentation to outline their plans for a Phase IIb trial using a 25mg psilocybin treatment combined with psychotherapy for Adjustment Disorder in palliative care. The trial is set to begin in Australia in Q4 2024, aiming to leverage the clinical benefits of natural psilocybin. The leadership team brings substantial experience from various sectors including pharmaceuticals and biotechnology, underscoring their capability in successful drug development. The company emphasizes their intellectual property and innovative treatment approaches as central to their growth strategy in the psychedelics market.
Read more →PBMPsyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC
Psyence Biomed has announced that the U.S. SEC has declared effective a registration statement related to a $25 million equity line of credit with White Lion Capital. This funding will assist the company in launching its Phase IIb clinical trial aimed at exploring the effects of non-synthetic psilocybin as a potential treatment for Adjustment Disorder in Palliative Care. The arrangement allows for share sales to White Lion over a 24-month period, supporting Psyence's long-term growth and innovation initiatives.
Read more →PBMPsyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024
Psyence Biomedical Ltd. (Nasdaq: PBM) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9th-11th, 2024. The company will present virtually, with its corporate presentation available on-demand starting September 9th. As the first life science biotech focusing on nature-derived psilocybin medicines listed on Nasdaq, Psyence is dedicated to developing effective treatments for mental health disorders.
Read more →PBMPsyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC
Psyence Biomedical Ltd. has entered into a $25 million common stock purchase agreement with White Lion Capital, LLC, which enables the company to sell shares over a 24-month period. The agreement is aimed at funding Psyence's upcoming Phase IIb clinical trial of psilocybin for Adjustment Disorder in Palliative Care. Psyence retains the option to terminate the agreement at its discretion without penalties. This partnership is viewed positively as it strengthens the company's financial position while advancing its clinical initiatives.
Read more →PBMPsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
Psyence Biomedical, associated with Psyence Group, has announced the export of nature-derived psilocybin to Australia and is set to commence a Phase IIb clinical trial. The trial will evaluate two therapeutic doses of psilocybin in a placebo-controlled setting. Despite the progress, uncertainties remain regarding the finalization of supply agreements and the potential impact on clinical trial timelines due to the termination of a previous licensing agreement. Overall, the company appears to be advancing towards significant milestones in psychedelic medicine.
Read more →PBMCOMMON STOCK PURCHASE AGREEMENT This Common Stock Purchase Agreement (this " Agreement ") is entered into effective as
Psyence Biomedical Ltd. has entered into a Common Stock Purchase Agreement with White Lion Capital, LLC, effective July 25, 2024. The agreement allows for the purchase and sale of up to $25 million in the company's common stock. This transaction is structured to comply with specific exemptions from the registration requirements of the Securities Act. Concurrently, a Registration Rights Agreement will ensure the resale of the securities involved.
Read more →PBMFIRST ADDENDUM TO THE LICENSE AGREEMENT
Filament Health Corp. and Psyence Group Inc. have executed a first addendum to their license agreement and commercial term sheet. This modification clarifies terms of the original agreement, ensuring continuity and consistency in their collaborative efforts. Each party will be responsible for their own legal costs associated with this addendum, reflecting their commitment to the partnership.
Read more →PBMPsyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
Psyence Biomedical Ltd. (Nasdaq: PBM) has announced the successful export of nature-derived psilocybin to Australia, preparing to initiate a Phase IIb clinical trial. This trial aims to evaluate the efficacy of psilocybin for treating Adjustment Disorder in palliative care settings, with expectation for commencement soon. While the company has established partnerships for support, it also faces challenges following the termination of its licensing agreement with Filament Health, necessitating the search for new suppliers. Despite these hurdles, Psyence remains confident in its progress towards innovative treatment solutions.
Read more →PBMPsyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Psyence Biomedical Ltd. has been notified by Nasdaq that it is not in compliance with the minimum bid price rule due to its shares trading below $1.00 for 30 consecutive business days. The company has been given 180 days to regain compliance, which will require its share price to stay above $1.00 for at least ten consecutive business days. If compliance is not achieved, Psyence may seek additional time or consider a reverse stock split. Despite this notification, the shares will continue to trade on Nasdaq, but there are inherent risks of delisting if non-compliance persists.
Read more →PBMPsyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase
Psyence Biomedical Ltd (Nasdaq: PBM) has announced its participation in the A.G.P. Virtual Healthcare Company Showcase, scheduled for May 21, 2024. Management will engage in 1x1 meetings with investors, aiming to promote the company's focus on developing psilocybin-based psychedelic medicines for mental health disorders. Psyence Biomed is recognized as the first life science biotechnology company in the world traded on Nasdaq, emphasizing an evidence-based approach to psychedelic therapeutics.
Read more →PBMPsyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)
Psyence Biomedical Ltd has listed its upcoming Phase IIb clinical trial on the Australian New Zealand Clinical Trials Registry, testing nature-derived psilocybin for Adjustment Disorder in advanced cancer patients. The trial will evaluate three dosing regimens in a randomized, double-blind, placebo-controlled format involving 84 participants, with results expected in 2025. This milestone reflects Psyence's ongoing efforts to develop effective psychedelic treatments within palliative care, with involvement from key partners. Nonetheless, the company's future success hinges on regulatory approvals and recruitment for the trial.
Read more →PBMPsyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
Psyence Biomedical has welcomed results from a study published in Molecular Psychiatry indicating that nature-derived psilocybin is more therapeutic than synthetic versions. The research, conducted by Hebrew University, suggests that natural psilocybin provides enhanced effects on neuroplasticity, vital for therapeutic efficacy. This positions Psyence as a unique player in the market, focusing on nature-derived solutions for Palliative Care applications. The company is advancing its Phase IIb clinical trial to evaluate nature-derived psilocybin for patients facing Adjustment Disorder due to serious illnesses.
Read more →PBMPsyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares
Psyence Biomedical Ltd. received two notifications from Nasdaq regarding deficiencies in its market valuation. The company must restore its market value of listed securities to at least $50 million and the value of publicly held shares to a minimum of $15 million within 180 days to maintain its listing status. While these notifications are not immediate suspensions, the company faces significant challenges to comply with Nasdaq's listing requirements. The performance must improve within the set deadline to prevent delisting.
Read more →PBMPsyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
Psyence Biomedical, an associate of Psyence Group, has received approval from the Australian Health Research Ethics Committee to initiate a Phase IIb clinical study. This study will explore the use of nature-derived psilocybin to treat Adjustment Disorder in patients undergoing palliative care due to cancer diagnoses. With an estimated 56.8 million people needing palliative care annually, this study aims to assess the impact of psilocybin on patient quality of life. The trials will be conducted in collaboration with iNGENū, a specialized Contract Research Organization.
Read more →PBMPsyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestones
Psyence Biomedical Ltd., trading under the ticker PBM on Nasdaq, recently issued a shareholder letter outlining its progress and goals. The company successfully merged with Newcourt Acquisition Corp., enhancing its capital access for developing nature-derived psilocybin treatments, particularly targeting Adjustment Disorder in Palliative Care. Psyence is also initiating a Phase IIb clinical trial following regulatory approvals in Australia, aiming to establish a leading position in an emerging market. The company is optimistic about future growth opportunities in the therapeutic use of psilocybin, supported by a substantial patent portfolio and adequate funding.
Read more →PBMPsyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division
Psyence Group Inc. announced the successful completion of the business combination with Newcourt Acquisition Corp, resulting in the spin-out and listing of Psyence Biomedical Ltd (PBM) on NASDAQ. This strategic move aims to reduce operating costs and streamline operations while allowing PBM to focus on clinical trials for psilocybin products in palliative care. The transition includes changes in management and a conditional transaction aimed at transferring non-clinical assets to another company, thereby allowing Psyence Group to maintain revenue streams without bearing overheads. The company's restructuring efforts reflect a shift towards an asset-light business model amid a competitive funding environment.
Read more →PBMPsyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
Psyence Biomedical's subsidiary, Psyence Australia, has obtained approval from the Australian Health Research Ethics Committee to start a Phase IIb clinical trial in Melbourne. This study will investigate the effectiveness of nature-derived psilocybin in treating Adjustment Disorder among cancer patients receiving palliative care. The trial aims to address a significant unmet medical need, with the collaboration of experienced Contract Research Organization iNGENū. The first patient is expected to be enrolled in Q2 2024, and results for the primary endpoint are anticipated by 2025.
Read more →PBMPsyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
Psyence Biomedical Ltd., a clinical-stage biotechnology company focused on psilocybin for mental health, has announced the completion of its merger with Newcourt Acquisition Corp. The company will be listed on NASDAQ with ticker 'PBM' starting January 26, 2024. This merger is expected to enhance Psyence Biomed's profile and attract North American investors, providing up to $10 million for clinical trials in palliative care. CEO Dr. Neil Maresky emphasized the merger as a pivotal moment for the company, aiming for advancements in health and wellness.
Read more →PBMPsyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination
Psyence Group Inc's subsidiary has signed a definitive agreement for convertible notes, aiming to secure up to $10 million from a U.S. investment firm. This funding is expected to aid in a planned business combination with Newcourt Acquisition Corp, positioning Psyence for a future Nasdaq listing. The financing includes conditions that must be met, indicating that while current sentiment is positive, there are risks surrounding the deal's completion.
Read more →PBMPsyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp
Psyence Group Inc. announced the SEC's approval of the registration statement for its proposed business combination with Newcourt Acquisition Corp. This marks a significant milestone as Psyence aims for a Nasdaq listing for its subsidiary, Psyence Biomed, which is valued at $50 million. The companies expect to close the transaction following the satisfaction of certain conditions. The deal also sets the stage for Psyence to begin a phase IIb clinical trial using psilocybin for palliative care, reinforcing its commitment to mental health advancements.
Read more →PBMPsyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement
Psyence Group Inc. has announced an amended agreement with Newcourt Acquisition Corp regarding a business combination. This filing includes a registration statement with the SEC and highlights a valuation of $50 million for Psyence's therapeutics division. However, the successful completion of the transaction hinges on necessary approvals and compliance with certain financial conditions. The partnership aims to provide Psyence with essential capital to advance its therapeutic strategies in mental health treatment, particularly in palliative care.
Read more →Competitive Position
How PBM ranks across every disease it competes inCompetitive Position is a premium feature
See how PBM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial